Numerous studies have found a strict association between thyroid carcinoma and activating somatic mutations in the BRAF oncogene demonstrating a high prevalence of these mutations mostly in the classical papillary thyroid carcinoma (PTC) and/or its more aggressive variant (including for instance tall cell variant-TCV and sclerosing variant of PTC-SVPTC) [7-8, 21-30]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.